See What HealthDay Can Do For You
Contact Us

Transurethral Therapy Helps Benign Prostate Hyperplasia

Durable results seen in most patients, but those with retention more likely to need retreatment

MONDAY, May 21 (HealthDay News) -- In most men with benign prostatic hyperplasia, treatment with transurethral microwave therapy leads to durable improvements. But patients with urinary retention may be more likely to require additional treatment, according to study findings published in the May issue of Urology.

Stavros Gravas, M.D., of University Hospital of Larissa, Greece, and colleagues treated 213 patients, 45 of whom had urinary retention, and followed the patients for a mean of 33.9 months up to a maximum of 65 months.

In patients without urinary retention, the researchers found that the mean maximal flow rate improved from 8.5 to 13.2 mL/s at four years, the International Prostate Symptom Score decreased from 20.3 to 12.5 at five years, and that quality-of-life scores significantly improved. In patients with urinary retention, these clinical outcomes remained stable during follow-up. They also found that patients without urinary retention were less likely than those with retention to require retreatment (28.6 percent versus 37.8 percent).

"Men in retention represent a specific group of patients with benign prostatic hyperplasia that, in general, are older, have poorer health status, and have a larger prostate and, therefore, are at increased risk of perioperative morbidity and mortality," the authors write.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.